F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Summary

This is a prospective, single-center, single-arm, exploratory pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of F182112 in combination with isatuximab and lenalidomide in transplant-eligible patients with newly diagnosed multiple myeloma. The study will also explore preliminary proof-of-concept signals of deep responses and minimal residual disease (MRD) negativity with this regimen, thereby informing the design of a subsequent phase II clinical trial.

Timeline

Start

2026-10-01

Primary completion

2027-10-09

Completion

2028-12-30

Drugs

Indications